Highlights and Quick Summary
- Annual Average Days of Payables for 2020 was 20418.1 (a -35.98% decrease from previous year)
- Annual Average Days of Payables for 2019 was 31891.88 (a Infinity% increase from previous year)
- Twelve month Average Days of Payables ending September 29, 2021 was 4344.2 (a -5.9% decrease compared to previous quarter)
- Twelve month trailing Average Days of Payables decreased by -78.72% year-over-year
Trailing Average Days of Payables for the last four month:
|29 Sep '21||29 Jun '21||30 Mar '21||30 Dec '20|
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Average Days of Payables of Phathom Pharmaceuticals, Inc.Most recent Average Days of Payablesof PHAT including historical data for past 10 years.
Interactive Chart of Average Days of Payables of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Average Days of Payables for the past 10 Years (both Annual and Quarterly)
Business Profile of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.